PatentsDB

Proteins and nucleic acids from meningitis/sepsis-associated Escherichia coli

US9334313B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-9334313-B2
Application numberUS-201414293967-A
CountryUS
Kind codeB2
Filing dateJun 2, 2014
Priority dateFeb 18, 2005
Publication dateMay 10, 2016
Grant dateMay 10, 2016

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

Disclosed herein are various open reading frames from a strain of E. coli responsible for neonatal meningitis (MNEC), and a subset of these that is of particular interest for preparing compositions for immunizing against MNEC infections.

First claim

Opening claim text (preview).

We claim: 1. A method of inducing an immune response in a subject comprising administering to the subject a polypeptide comprising: (a) an amino acid sequence having at least 95% sequence identity to SEQ ID NO: 810; (b) a fragment of SEQ ID NO: 810, wherein the fragment of SEQ ID NO: 810 comprises at least 20 consecutive amino acids from SEQ ID NO: 810 and the fragment is a B-cell epitope for extra intestinal pathogenic E.coli (ExPEC) and meningitis associated E.coli (MNEC); or (c) an amino acid sequence having at least 95% sequence identity to SEQ ID NO: 810 and including a fragment of at least 20 consecutive amino acids from SEQ ID NO: 810 that includes a B-cell epitope of the amino acid sequence of SEQ ID NO: 810. 2. The method of claim 1 , wherein the immune response is a protective immune response against an ExPEC infection. 3. The method of claim 1 , wherein the immune response is a protective immune response against an MNEC infection. 4. The method of claim 1 , wherein the polypeptide is administered as a pharmaceutical composition in admixture with a pharmaceutically acceptable carrier. 5. The method of claim 1 , wherein two are more polypeptides comprising (a), (b), or (c) are administered to the subject. 6. The method of claim 1 , wherein the polypeptide is administered as a composition further comprising an adjuvant.

Assignees

Inventors

Classifications

Patent family

Related publications grouped by family.

View patent family 36917149

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US9334313B2 cover?
Disclosed herein are various open reading frames from a strain of E. coli responsible for neonatal meningitis (MNEC), and a subset of these that is of particular interest for preparing compositions for immunizing against MNEC infections.
Who is the assignee on this patent?
Novartis Vaccines & Diagnostic, Craig J Venter Inst Inc, Glaxosmithkline Biolog Sa
What technology area does this patent fall under?
Primary CPC classification C07K14/245. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue May 10 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).